Personalized Vaccine for Liver Cancer Shows Promise in Clinical Trial

Personalized Vaccine for Liver Cancer Shows Promise in Clinical Trial

A global clinical trial, led by researchers at the Johns Hopkins Kimmel Cancer Center and its Convergence Institute, has found that adding a personalized anti-tumor vaccine to standard immunotherapy is safe and about twice as likely to shrink cancer as standard immunotherapy alone for patients with hepatocellular carcinoma, the most common type of liver cancer.

 READ HERE
SEE ALL NEWS
Recent Posts
Immunotherapy Combination May Benefit Patients with Transplanted Kidneys and Advanced Skin Cancers Colorectal Cancer Gene Implicated in Broad Range of Solid Tumors Johns Hopkins Investigators Develop Novel Treatment for T-cell Leukemias and Lymphomas Robotic surgeon precisely removes cancerous tumors Podcast: Pancreatitis and Pancreatic Cancer Monitoring levels of DNA in the blood could indicate treatment response Age-Related Changes in Fibroblast Cells Promote Pancreatic Cancer Growth and Spread Amount Of Repetitive DNA In Blood Hints at Cancer Early Podcast: Colorectal Cancer